Lobbying registration dated 2026-04-02
Registrant: Iain Graham
Client: Novo Nordisk Canada Inc.
Targeted institutions:
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Indigenous Services Canada (ISC)
Global Affairs Canada (GAC)
Patented Medicine Prices Review Board (PMPRB)
Canada Foundation for Innovation
Parks Canada (PC)
Canadian Heritage (PCH)
Intergovernmental Affairs Secretariat (IGA)
Finance Canada (FIN)
Canadian Human Rights Tribunal (CHRT)
House of Commons
Employment and Social Development Canada (ESDC)
Agriculture and Agri-Food Canada (AAFC)
National Research Council (NRC)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Prime Minister's Office (PMO)
Innovation, Science and Economic Development Canada (ISED)
Legislative bills: C-64
S-201
Acts: Pharmacare Act
Government funding received:
Lobbying activity details:
Bill C-64, the Pharmacare Act, with respect to definitional questions related to terms contained in Section 6.1, and concerns regarding the increased risk of drug shortages.
Advocate for the implementation of a federal diabetes and obesity strategy.
Free trade agreements as they relate to the biopharmaceutical industry.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
Communication around existing drug shortages and shared solutions to mitigate the impact on Canadians.
Advocating in support of Bill S-201, An Act respecting a national framework on sickle cell disease.
Advocate for the establishment of public-private partnerships to support chronic disease prevention.